TrialRespiratory research2022

Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial.

Vincent Cottin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.